Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 (Coronavirus Disease 2019) Patients (COLHEART-19)
Latest Information Update: 07 Nov 2022
Price :
$35 *
At a glance
- Drugs Colchicine (Primary)
- Indications Cardiovascular disorders; COVID 2019 infections
- Focus Therapeutic Use
- Acronyms COLHEART-19
- 14 Feb 2022 Status changed from active, no longer recruiting to completed.
- 14 Jun 2021 Planned End Date changed from 25 Apr 2021 to 8 Sep 2021.
- 14 Jun 2021 Planned primary completion date changed from 25 Apr 2021 to 8 Sep 2021.